Bristol-Myers Squibb and Concerto HealthAI sign multi-year real-world evidence agreement
A short entry: a summary of the public record, checked against its sources, not yet read and analysed by Gianluca. How the register works
Bristol-Myers Squibb and Concerto HealthAI announced a multi-year strategic agreement on 29 March 2019 under which BMS will use Concerto HealthAI's EurekaHealth technology platform to investigate novel health economic outcomes and clinical development synthetic control arm studies.
What happened
- Announced 29 March 2019 as a multi-year strategic agreement.
- BMS will use Concerto HealthAI's EurekaHealth platform for synthetic control arm studies and novel health economic outcomes work.
- Stated aims include advancing the use of RWE for regulatory purposes, validating clinical application of AI solutions, and executing clinical studies.
- Concerto HealthAI integrates data from sources including CancerLinQ, developed and operated by CancerLinQ LLC, a non-profit subsidiary of ASCO, and is an exclusive licensee.
- The agreement follows the FDA's 21st Century Cures Act and the FDA's December 2018 framework to assess RWE in regulatory decisions.
- Quoted: Concerto HealthAI CEO Jeff Elton and Jeff Conklin, head of business insights and analytics at Bristol-Myers Squibb.
Who is involved
Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing and delivering innovative medicines that help patients overcome serious diseases.
Concerto HealthAI, a SymphonyAI Group portfolio company, is a technology leader in Definitive Real-World Data (RWD) and AI solutions for Precision Oncology.
Sources
- pharmaphorum.com — primary
- stockanalysis.com — party background
- pharmaceutical-technology.com — party background
- fiercehealthcare.com — party background
- hitconsultant.net — party background
Announced 2019-03-29